Safety and Effectiveness Study of rhGAA in Patients With Advanced Late-Onset Pompe Disease Receiving Respiratory Support
PHASE3CompletedINTERVENTIONAL
Enrollment
5
Participants
Timeline
Start Date
December 31, 2005
Primary Completion Date
March 31, 2007
Study Completion Date
June 30, 2007
Conditions
Pompe Disease (Late-onset)Glycogen Storage Disease Type II (GSD-II)Acid Maltase Deficiency DiseaseGlycogenosis 2
Interventions
BIOLOGICAL
Myozyme
20 mg/kg qow
Trial Locations (1)
92380
Hopital Raymond Poincare, Garches
All Listed Sponsors
lead
Genzyme, a Sanofi Company
INDUSTRY
NCT00268944 - Safety and Effectiveness Study of rhGAA in Patients With Advanced Late-Onset Pompe Disease Receiving Respiratory Support | Biotech Hunter | Biotech Hunter